Enterome is a clinical-stage biopharmaceutical company focused on developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases.
Enterome’s pioneering approach to drug discovery is based on its unique ability to decode the interaction between the gut microbiome and the immune system.
Enterome’s drug discovery platform uses best-in-class biocomputational tools and bioassays to identify novel therapeutics from its proprietary database of 20 million full-length gut microbiome proteins. This platform is highly productive and has already generated multiple pipelines of transformative drug candidates, targeting a broad range of therapeutic areas.
Enterome’s potentially first-in-class small protein and peptide drug candidates modulate the immune system by closely mimicking the structure, effect or actions of specific antigens, hormones or cytokines. The Company is presently advancing two pipelines of distinct drug candidates – OncoMimicsTM and EndoMimicsTM – which have the potential to address cancer, inflammatory and autoimmune diseases, respectively.
full length proteins from the gut microbiome
17 patent families filed
3 in-licensed patent families,
4 Trademarks filed
Our leadership team
Board of Directors
Enterome signed a global licensing, co-development and co-promotion agreement with Takeda. The agreement covers Enterome’s investigational drug candidate sibofimloc (also called TAK-018) in patients with Crohn’s disease, with the potential to expand to other gastrointestinal (GI) disorders.
This first-in-class small molecule drug candidate acts by blocking the FimH virulence factor and is being advanced by Takeda through a Phase 2 clinical trial in post-operative Crohn’s disease. Enterome retains a significant profit share in the US.
Enterome signed a clinical trial collaboration and supply agreement with Bristol Myers Squibb (BMS) March 2021 to support EO2401, an OncoMimicsTM vaccine in clinical development.
As a result of this agreement, BMS has committed to the supply, free of charge, nivolumab in sufficient quantity for patients participating in the combined therapy clinical trials such as Rosalie (EOGBM1-18) and Spencer (EOADR1-19).
Enterome was established in 2012 and has raised €96 million in financing rounds with private equity funds, strategic investors and in loans.